JP Morgan Chase
MRNA icon

JP Morgan Chase’s Moderna MRNA Stock Holding History

JP Morgan Chase’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.09M Buy
101,700
+10,700
+12% +$554K ﹤0.01% 3121
2026
Q1 		$4.39M Sell
91,000
-30,000
-25% -$1.4M ﹤0.01% 3441
2025
Q4 		$3.57M Buy
121,000
+120,800
+60,400% +$3.28M ﹤0.01% 3619
2025
Q3 		$5.17K Sell
200
-20,300
-99% -$566K ﹤0.01% 6771
2025
Q2 		$566K Buy
20,500
+11,000
+116% +$290K ﹤0.01% 4713
2025
Q1 		$269K Buy
9,500
+6,100
+179% +$216K ﹤0.01% 5110
2024
Q4 		$141K Sell
3,400
-200
-6% -$9.56K ﹤0.01% 5619
2024
Q3 		$241K Sell
3,600
-93,800
-96% -$8.61M ﹤0.01% 5325
2024
Q2 		$11.6M Buy
+97,400
New +$12.3M ﹤0.01% 2331
2024
Q1 		– Sell
-118,700
Closed -$11.8M – 7707
2023
Q4 		$11.8M Sell
118,700
-157,200
-57% -$13.2M ﹤0.01% 2306
2023
Q3 		$28.5M Buy
275,900
+160,000
+138% +$17.8M ﹤0.01% 1424
2023
Q2 		$14.1M Sell
115,900
-200
-0.2% -$26.7K ﹤0.01% 1998
2023
Q1 		$17.8M Buy
116,100
+89,500
+336% +$14.8M ﹤0.01% 1763
2022
Q4 		$4.78M Buy
26,600
+1,200
+5% +$196K ﹤0.01% 2858
2022
Q3 		$3M Buy
25,400
+15,400
+154% +$2.34M ﹤0.01% 3150
2022
Q2 		$1.43M Sell
10,000
-190,000
-95% -$27.2M ﹤0.01% 3826
2022
Q1 		$34.5M Sell
200,000
-32,200
-14% -$5.42M ﹤0.01% 1382
2021
Q4 		$59M Buy
232,200
+197,200
+563% +$57.7M 0.01% 1125
2021
Q3 		$13.5M Buy
+35,000
New +$12.9M ﹤0.01% 2122
2021
Q1 		– Sell
-37,300
Closed -$3.9M – 6238
2020
Q4 		$3.9M Sell
37,300
-160,000
-81% -$16.2M ﹤0.01% 3004
2020
Q3 		$13.9M Buy
197,300
+167,300
+558% +$11.7M ﹤0.01% 1768
2020
Q2 		$1.93M Hold
30,000
– – ﹤0.01% 3126
2020
Q1 		$899K Buy
+30,000
New +$690K ﹤0.01% 3461

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

JP Morgan Chase's MRNA Position: Q2 2026 in Review

JP Morgan Chase reduced its Moderna (MRNA) stake by 36% in Q2 2026, selling an estimated $24.8M and leaving 837,452 shares worth $59.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1351.

JP Morgan Chase first reported a position in MRNA in Q4 2018 and has held it in 31 quarters since. The position peaked at $492M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • JP Morgan Chase held 837,452 shares of Moderna worth $59.5M as of Q2 2026.
  • JP Morgan Chase sold 480,149 Moderna shares in Q2 2026, an estimated $24.8M.
  • Moderna made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1351 holding.
  • JP Morgan Chase first reported a position in Moderna in Q4 2018 and has held it in 31 quarters since.
  • JP Morgan Chase's Moderna position peaked at $492M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.